SCIENTIFIC RESEARCH OF THE MICROFLORA OF THE COLON IN PATIENTS WITH COLORECTAL CANCER
DOI:
https://doi.org/10.32782/2786-9067-2024-28-10Keywords:
colorectal cancer, colon, microflora, treatmentAbstract
The medical definition of a malignant tumor of the mucous membrane of the large intestine is called colorectal cancer (CRC). The large intestine in humans is the part of the intestine from the ileocecal valve (the structure that separates the small and large intestines) to the anus (anus). Parts of the large intestine – sigmoid colon, colon, cecum, rectum. Sometimes the rectum is isolated separately. Tumors show similar symptoms, the same complications occur in different parts of the colon and have similar mechanisms. That is why all these diseases are united under one term “colorectal cancer”. This is a dangerous disease that requires preventive, educational measures and comprehensive treatment. The purpose of the work is the study of research and scientific developments regarding disturbances of the microflora of the colon in patients with colorectal cancer. Materials and methods. Review and generalization of the literature, modern scientific and experimental studies, which are related to the study of this issue. Research results: Approximately 45% of patients diagnosed with CRC die from this pathology, despite treatment. Studies confirm that despite the organization and implementation of screening measures, 14.7–60.0% of patients with CRC are diagnosed for the first time due to the occurrence of complications – acute intestinal obstruction, bleeding, perforation and peritonitis. Approximately 45% of patients diagnosed with CRC die from this pathology, despite treatment. Studies confirm that despite the organization and implementation of screening measures, 14.7–60.0% of patients with CRC are diagnosed for the first time due to the occurrence of complications – acute intestinal obstruction, bleeding, perforation and peritonitis. Conclusion. In the case of disturbances in the functioning of the intestinal microflora, the risk of developing a significant number of diseases (infectious, metabolic, autoimmune, oncological, neurological and endocrine), including colorectal cancer, increases.
References
Бойко В. В., Лихман В. М., Шевченко А. М., Меркулов А. О., Османов Р. Р. Застосування малоінвазивних операцій у лікуванні хворих на колоректальний рак, ускладнений непрохідністю кишечника. Міжнародний медичний журнал. 2018. Т. 24, № 2. С. 16–19. URL: http://www.irbis-nbuv.gov.ua/cgi.
Захараш М. П., Харченко Н. В., Музыка С. В. Скринінг передракових захворювань та раку товстої кишки : методичні рекомендації. Київ : Медицина, 2010. 18 с.
Мельничук Н. І., Шабат Г. І., Чурпій І. К. Коротко про скринінг колоректального раку. ArtofMedicine. 2019. № 3 (11). С. 105–109. URL: https://art-of-medicine.ifnmu.edu.ua/index.php/aom/article/view/366.
Ткач С. М., Пучков К. С. Сизенко А. К. Кишкова мікробіота в нормі та при патології. Сучасні підходи до діагностики та лікування кишкового дисбіозу. Київ : Твіса ЛТД, 2014. 149 с.
Федоренко З. П., Михайлович Ю. Й., Гулак Л. О. та ін. Рак в Україні, 2017–2018. Захворюваність, смертність, показники діяльності онкологічної служби. Бюлетень Національного канцер-реєстру України, № 20. Київ : Поліум, 2019. 102 с.
Федоренко З. П., Колеснік О. О., Гулак Л. О., Рижов А. Ю., Сумкіна О. В. Колоректальний рак в Україні: епідеміологічні та організаційні аспекти проблеми. Practical oncology. 2019. Вип. 2. № 2 С. 2–9. https://doi.org/10.22141/2663-3272.2.2.2019.176026.
American Cancer Society. Colorectal Cancer Facts & Figures 2017–2019. Atlanta: American Cancer Society, 2017. 36 p.
Arnold M., Sierra S., Laversanne M.et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017. Vol. 66 (4). P. 683–691. DOI: 10.1136/gutjnl-2015-310912. URL: https://gut.bmj.com/content/66/4/683.
Atkin W.S., Edwards R., Kralj-Hans I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010. Vol. 375. P. 1624–1633. DOI: 10.1016/S0140-6736(10)60551-X.
Boleij A., Tjalsma H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease.Lancet Infectious Diseases. 2013. Vol. 13, № 8. Р. 719–724. DOI: 10.1016/S1473-3099(13)70107-5.
Durban A., Abellan J., Ponce M., et al. Assessing GutMicrobial Diversity from Feces and Rectal Mucosa.Aquatic Microbial Ecology. 2011. Vol. 61. P. 123–133. DOI: 10.1007/s00248-010-9738-y.
Evrard B., Coudeyras S., Dosgilbert A., et al. Dose-dependent immunomodulation of human dendritic cells by the probiotic Lactobacillus rhamnosus Lcr35. PLoS One. 2011. Vol. 6, No. 4. Р. e18735. DOI: 10.1371/journal.pone.0018735.
Flint H.J., Scott K.P., Louis P., et al. The role of the gut microbiota in nutrition and health. Nature Reviews Gastroenterology & Hepatology. 2012. No. 9 (10). P. 577–589. DOI: 10.1038/nrgastro.2012.156.
Global Cancer Observatory: Colorectal cancer. [Internet]. Lyon. Fr. International Agency for Research on Cancer. Cancer 2018. URL: https://gco.iarc.fr/today.
Gur C., Ibrahim Y., Isaacson B., et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015. Vol. 42, No. 2. P. 344–355. DOI: 10.1016/j.immuni.2015.01.010.
Hamer H.M., Jonker S.D., Venema K. Review article: the role of butyrate on colonic function. Alimentary Pharmacology & Therapeutics. 2008. Vol. 15, No. 27 (2). P. 104–119. DOI: 10.1111/j.1365-2036.2007.03562.x.
Klein R.S., Recco R.A., Catalano M.T. [et al.] Association of Streptococcus bovis with carcinoma of the colon. New England Journal of Medicine. 1977. Vol. 297, No. 15. P. 800–802. DOI: 10.1056/NEJM197710132971503.
Koropatkin N.M., Cameron E.A., Martens E.C. How Glycan Metabolism Shapes the Human Gut Microbiota. Nature Reviews Microbiology. 2012. Vol. 10. P. 323–335. DOI: 10.1038/nrmicro2746.
Kostic A.D., Chun E., Robertson L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host & Microbe. 2013. Vol. 14, No. 2. P. 207–215. DOI: 10.1016/j.chom.2013.07.007.
Kye Bong-Hyeon et al. The optimal time interval between the placement of self-expandable metallic stent and elective surgery in patients with obstructive colon cancer. Scientific Reports. 2020. Vol. 10. (1). P. 9502. URL: https://www.nature.com/articles/s41598-020-66508-6.
McCoy A.N., Araujo-Perez F., Azcarate-Peril A., et al. Fusobacterium is associated with colorectal adenomas. PLoS ONE. 2013. Vol. 8. P. e53653. DOI: 10.1371/journal.pone.0053653.
Papatheodoridis G.V., Triantafyllou K., Tzouvala M., Paspatis G., Xourgias V., Karamanolis D.G. Characteristics of rectosigmoid adenomas as predictors of synchronous advanced proximal colon neoplasms. American Journal of Gastroenterology. 1996. Vol. 91. P. 1809–1913.
Pourhoseingholi M.A. Epidemiology and burden of colorectal cancer in Asia-Pacific region: what shall we do now? Translational Gastrointestinal Cancer. 2014. Vol. 3, No 4. URL: http://tgc.amegroups.com /article/view/4445/5581/.
Prakash S., Rodes L., Coussa-Charley M. [et al.] Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics. 2011. No. 5. P. 71–86. Doi: 10.2147/BTT.S19099.
Renzi C. et al. Contrasting effects of comorbidities on emergency colon cancer diagnosis: a longitudinal data-linkage study in England. BMC Health Services Research. 2019. Vol. 19. P. 1–14. DOI: 10.1186/s12913-019-4075-4.
Rex D.K., Chak A., Vasudeva R., et al. Prospective determination of distal colon findings in average-risk patients with proximal colon cancer. Gastrointestinal Endoscopy. 2011. Vol. 49. P. 727–730. DOI: 10.1016/s0016-5107(99)70290-7.
Toprak U.N., Yagci A., Gulluoglu B.M. [et al.] A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clinical microbiology and infectious. 2006. Vol. 12, No. 8. P. 782–786. DOI: 10.1111/j.1469-0691.2006.01494.x.
UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. British Medical Journal. 2004. Vol. 329 (7458). P. 133. DOI: 10.1136/bmj.38153.491887.7C.
Walter J., Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annual Review of Microbiology. 2011. No. 65. P. 411–429. DOI: 10.1146/annurev-micro-090110-102830.
Wu N., Yang X., Zhang R. et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients.Microbial Ecology. 2013. Vol. 66. P. 462–470. DOI: 10.1007/s00248-013-0245-9.
